Literature DB >> 22486731

Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting.

Arjuna Priyadarsin De Silva1, Shanika Dulanjalee Nandasiri, Janaki Hewavisenthi, Aresha Manamperi, Madurangi Prasadi Ariyasinghe, Anuradha Supun Dassanayake, Derek P Jewell, Hithanadura Janaka de Silva.   

Abstract

BACKGROUND AND AIMS: There is evidence for low-grade inflammation in the pathophysiology of post-infectious irritable bowel syndrome (IBS). We assessed the degree of subclinical intestinal mucosal inflammation in diarrhea-predominant IBS (IBS-D) in a tropical setting.
MATERIAL AND METHODS: In a prospective study over 1 year, we investigated 49 patients with IBS-D (cases; median age 34 years (range 18-59); M:F 36:13), diagnosed on Rome III criteria. 14 individuals with a family history of colon cancer (median age 46.5 years (range 23-56); M:F 6:8) were selected as controls. Stools of cases and controls were tested for calprotectin. During colonoileoscopy, serial biopsies were obtained. Mucosal mast cells, neutrophils, eosinophils and lymphocytes/plasma cell infiltrate were quantified. Tissue expression of IL-8 and IL-10 was assessed in biopsies by semi-quantitative RT-PCR.
RESULTS: A history suggestive of an episode of infectious diarrhea (ID) was present in 16/49 cases and 0/14 controls (p = 0.013). In cases, there were significantly more mucosal mast cells in the ileum and all segments of colon and significantly more eosinophils in the cecum. Tissue expression of IL-8 was significantly higher and IL-10 significantly lower in cases compared with controls (target/standard cDNA ratio, median (range) IL-8: 1.25 (0.75-2) vs. 0.85 (0.63-1.3), p < 0.0001, Mann-Whitney U test; IL-10: 0.33 (0-0.63) vs. 0.55 (0.5-0.7), p < 0.0001). There was a significant inverse correlation between IL-8 and IL-10 expression (Pearson correlation, (-) 0.509; p < 0.01).
CONCLUSION: There was evidence of subclinical intestinal mucosal inflammation in patients with IBS-D. The finding of increased eosinophils is novel, and may be of special relevance to IBS-D in the tropics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22486731     DOI: 10.3109/00365521.2012.666672

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  13 in total

1.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

2.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

3.  Low prevalence of 'classical' microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea.

Authors:  Ida Hilmi; Juanda Leo Hartono; Jayalakshmi Pailoor; Sanjiv Mahadeva; Khean-Lee Goh
Journal:  BMC Gastroenterol       Date:  2013-05-08       Impact factor: 3.067

Review 4.  Current insights into the innate immune system dysfunction in irritable bowel syndrome.

Authors:  Nikolaos Lazaridis; Georgios Germanidis
Journal:  Ann Gastroenterol       Date:  2018-01-18

5.  The relationship between mucosal inflammatory cells, specific symptoms, and psychological functioning in youth with irritable bowel syndrome.

Authors:  Meenal Singh; Vivekanand Singh; Jennifer V Schurman; Jennifer M Colombo; Craig A Friesen
Journal:  Sci Rep       Date:  2020-07-20       Impact factor: 4.379

6.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS).

Authors:  Paul Moayyedi; Christopher N Andrews; Glenda MacQueen; Christina Korownyk; Megan Marsiglio; Lesley Graff; Brent Kvern; Adriana Lazarescu; Louis Liu; William G Paterson; Sacha Sidani; Stephen Vanner
Journal:  J Can Assoc Gastroenterol       Date:  2019-01-17

Review 7.  Potential neuro-immune therapeutic targets in irritable bowel syndrome.

Authors:  Maite Casado-Bedmar; Åsa V Keita
Journal:  Therap Adv Gastroenterol       Date:  2020-04-09       Impact factor: 4.409

8.  Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health.

Authors:  Georgios Katinios; Maite Casado-Bedmar; Susanna A Walter; Maria Vicario; Ana M González-Castro; Olga Bednarska; Johan D Söderholm; Henrik Hjortswang; Åsa V Keita
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

9.  Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis.

Authors:  Ratnakar Shukla; Ujjala Ghoshal; Prabhat Ranjan; Uday C Ghoshal
Journal:  J Neurogastroenterol Motil       Date:  2018-10-01       Impact factor: 4.924

10.  Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Eloísa Salvo-Romero; Cristina Martínez; Beatriz Lobo; Bruno K Rodiño-Janeiro; Marc Pigrau; Alejandro D Sánchez-Chardi; Ana M González-Castro; Marina Fortea; Cristina Pardo-Camacho; Adoración Nieto; Elba Expósito; Danila Guagnozzi; Amanda Rodríguez-Urrutia; Inés de Torres; Ricard Farré; Fernando Azpiroz; Carmen Alonso-Cotoner; Javier Santos; María Vicario
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.